PROTAC Therapy for Parkinson's Disease

Migration, Crosslink

📖

PROTAC Therapy for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-protac-therapy-parkins

📖 Wiki Page

therapeutic2799 wordssynced 2026-04-02

PROTAC Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PROTAC Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Target "undruggable" proteins</td>
<td>Can degrade proteins lacking active sites for inhibitor binding</td>
</tr>
<tr>
<td class="label">Catalytic mechanism</td>
<td>One PROTAC molecule can degrade multiple target proteins</td>
</tr>
<tr>
<td class="label">Durable effect</td>
<td>Protein depletion persists after drug clearance</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Can distinguish mutant from wild-type proteins</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Direct α-syn binder</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Oligomer-selective</td>
<td>Biotech A</td>
</tr>
<tr>
<td class="label">Autotac</td>
<td>Research labs</td>
</tr>
<tr>
<td class="label">E3 Ligase</td>
<td>CNS Expression</td>
</tr>
<tr>
<td class="label">Cereblon (CRBN)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">VHL</td>
<td>Low</td>
</tr>
<tr>
<td class="label">cIAP1</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">DCAF16</td>
<td>High in CNS</td>
</tr>
<tr>
<td class="label">RNF4</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Ratio

...

PROTAC Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">PROTAC Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Target "undruggable" proteins</td>
<td>Can degrade proteins lacking active sites for inhibitor binding</td>
</tr>
<tr>
<td class="label">Catalytic mechanism</td>
<td>One PROTAC molecule can degrade multiple target proteins</td>
</tr>
<tr>
<td class="label">Durable effect</td>
<td>Protein depletion persists after drug clearance</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Can distinguish mutant from wild-type proteins</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Direct α-syn binder</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Oligomer-selective</td>
<td>Biotech A</td>
</tr>
<tr>
<td class="label">Autotac</td>
<td>Research labs</td>
</tr>
<tr>
<td class="label">E3 Ligase</td>
<td>CNS Expression</td>
</tr>
<tr>
<td class="label">Cereblon (CRBN)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">VHL</td>
<td>Low</td>
</tr>
<tr>
<td class="label">cIAP1</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">DCAF16</td>
<td>High in CNS</td>
</tr>
<tr>
<td class="label">RNF4</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>Lewy body formation, propagation</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Most common familial PD gene</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>Lysosomal dysfunction in PD</td>
</tr>
<tr>
<td class="label">Tau (4R)</td>
<td>CBD/PSP overlap</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">α-syn PROTAC</td>
<td>Unknown</td>
</tr>
<tr>
<td class="label">Molecular glue</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Implication</td>
</tr>
<tr>
<td class="label">Large molecular weight</td>
<td>1500-3000 Da exceeds typical drug properties</td>
</tr>
<tr>
<td class="label">Polar surface area</td>
<td>Limits membrane permeability</td>
</tr>
<tr>
<td class="label">P-gp efflux</td>
<td>Active transport out of CNS</td>
</tr>
<tr>
<td class="label">E3 Ligase</td>
<td>Brain Expression</td>
</tr>
<tr>
<td class="label">CRBN (cereblon)</td>
<td>High</td>
</tr>
<tr>
<td class="label">VHL</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">cIAP1</td>
<td>Low</td>
</tr>
<tr>
<td class="label">DCAF15</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Traditional Inhibitors</td>
</tr>
<tr>
<td class="label">Target scope</td>
<td>Druggable active sites</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Requires constant occupancy</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>May have off-target effects</td>
</tr>
<tr>
<td class="label">Resistance</td>
<td>Point mutations in binding site</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ARV-102</td>
<td>LRRK2</td>
</tr>
<tr>
<td class="label">α-syn PROTAC</td>
<td>Alpha-synuclein</td>
</tr>
<tr>
<td class="label">GBA PROTAC</td>
<td>GBA</td>
</tr>
<tr>
<td class="label">Tau PROTAC</td>
<td>Tau</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ARV-102</td>
<td>LRRK2</td>
</tr>
<tr>
<td class="label">α-syn PROTAC programs</td>
<td>α-syn</td>
</tr>
<tr>
<td class="label">Autotac</td>
<td>α-syn aggregates</td>
</tr>
<tr>
<td class="label">Tau PROTACs</td>
<td>4R-tau</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">PROTAC + L-dopa</td>
<td>Degrade LRRK2 + dopamine replacement</td>
</tr>
<tr>
<td class="label">PROTAC + anti-α-syn antibodies</td>
<td>Complement mechanisms</td>
</tr>
<tr>
<td class="label">PROTAC + gene therapy</td>
<td>Different mechanisms</td>
</tr>
<tr>
<td class="label">Multiple PROTACs</td>
<td>Degrade multiple targets</td>
</tr>
</table>

Overview

PROTAC (Proteolysis-Targeting Chimeras) therapy represents a novel therapeutic approach for Parkinson's disease (PD) that leverages the ubiquitin-proteasome system (UPS) to selectively degrade disease-causing proteins. Unlike traditional small-molecule inhibitors, PROTACs can induce degradation of "undruggable" protein targets by bringing them into proximity with E3 ubiquitin ligases[@cao2023]. This technology has transformed drug discovery by enabling targeting of proteins previously considered undruggable, and is now being applied to neurodegenerative diseases with particular promise for PD[@guenette2024].

Parkinson's disease is characterized by the accumulation of toxic protein aggregates, including alpha-synuclein in Lewy bodies and Lewy neurites, and mutant LRRK2 protein that disrupts cellular homeostasis. Traditional small-molecule approaches have struggled to address these targets effectively. PROTACs offer a fundamentally different approach: rather than simply inhibiting a protein's function, they promote its complete removal from the cell.

Molecular Mechanism of PROTACs

PROTACs offer several key advantages over traditional pharmacological approaches:

Mechanism of Action

PROTACs are bifunctional molecules consisting of:

Target-binding moiety: Binds to the disease-causing protein (e.g., alpha-synuclein, LRRK2)
E3 ligase-binding moiety: Recruits an E3 ubiquitin ligase (e.g., cereblon, VHL, cIAP1)

Structure and Design

PROTACs are bifunctional molecules consisting of three components:

Target-binding moiety: Binds to the disease-causing protein (e.g., alpha-synuclein, LRRK2, GBA)

Linker: Spacer that connects the two functional ends, optimized for cell permeability and ternary complex formation

E3 ligase-binding moiety: Recruits an E3 ubiquitin ligase (e.g., cereblon, VHL, cIAP1, DCAF16)

Mermaid diagram (expand to render)

Ternary Complex Formation

The key to PROTAC mechanism is the formation of a ternary complex between the target protein, PROTAC molecule, and E3 ligase. This interaction brings the E3 ligase into proximity with the target, enabling ubiquitination:

Cooperativity: Optimal PROTACs show positive cooperativity in ternary complex formation
Stoichiometry: Each PROTAC molecule can catalyze multiple ubiquitination events (catalytic mechanism)
Selectivity: The target-binding moiety determines which proteins are recruited to the E3 ligase

Ubiquitin-Proteasome System Engagement

Once the ternary complex forms, the E3 ligase catalyzes transfer of ubiquitin molecules to the target protein:

Ubiquitin activation: E1 enzyme activates ubiquitin

Ubiquitin transfer: E2 enzyme transfers ubiquitin to E3 ligase

Target ubiquitination: E3 ligase transfers ubiquitin to lysine residues on target

Proteasomal recognition: Polyubiquitinated target is recognized by the 26S proteasome

Target degradation: Target is unfolded and degraded into peptides

Key Protein Targets for PD PROTACs

Alpha-Synuclein

Alpha-synuclein is the primary component of Lewy bodies, the characteristic protein aggregates in PD brain. Several PROTAC programs are targeting alpha-synuclein:

Challenges: Alpha-synuclein is a natively unfolded protein without well-defined binding pockets, making small-molecule targeting difficult. Current approaches use various α-synuclein-binding motifs including small molecules that stabilize the protein's native state, peptides derived from E3 ligase domains, and engineered protein binders[@tschantz2022].

LRRK2

LRRK2 (Leucine-Rich Repeat Kinase 2) is the most common genetic cause of familial PD, with the G2019S mutation causing approximately 1-5% of all PD cases. LRRK2 inhibitors have been in clinical development, but PROTACs offer advantages:

ARV-102 (Anavoris/Arvinas): Most advanced LRRK2 PROTAC, brain-penetrant, degrades mutant LRRK2 G2019S selectively[@liu2024]
Selective degradation: Can target mutant protein while preserving wild-type function
Durable effect: Catalytic mechanism may provide longer duration of action

Studies have shown that LRRK2 PROTACs can selectively degrade mutant LRRK2 while sparing wild-type, addressing a key limitation of ATP-competitive inhibitors[@bjorklund2022][@chen2024].

GBA

GBA (Glucosylceramidase) mutations are the most common genetic risk factor for PD, present in 5-10% of all PD cases. GBA deficiency leads to lysosomal dysfunction and alpha-synuclein accumulation:

PROTACs can degrade mutant GBA to reduce toxic gain-of-function
Alternatively, PROTACs can upregulate compensatory lysosomal enzymes
Current programs in preclinical development[@zhang2026]

Tau

Tau pathology in PD is most relevant for Parkinsonism syndromes like Corticobasal Degeneration (CBD) and Progressive Supranuclear Palsy (PSP), which share features with PD:

4R-tau isoform predominates
PROTACs can target tau aggregates directly
Combined targeting of tau and alpha-synuclein may be beneficial in synucleinopathies[@brown2026]

E3 Ligase Considerations for CNS PROTACs

Brain-Penetrant E3 Ligase Recruitment

A major challenge for CNS PROTACs is the limited expression of certain E3 ligases in the brain:

New E3 ligases are being explored for brain-targeted PROTACs, including DCAF16, RNF4, and novel cereblon modulators[@toman2023][@liu2025b][@song2025].

Strategies for Enhanced Brain Penetration

Optimized linkers: Shorter, more polar linkers improve BBB penetration

E3 ligase selection: Using brain-enriched E3 ligases like DCAF16

Conjugate design: Brain-penetrant E3 recruiters

Formulation approaches: Nanoparticle delivery, prodrug strategies[@tian2026]

Molecular Steps

Mermaid diagram (expand to render)

Key Targets for PD

Ubiquitin-Proteasome System

The UPS is the primary cellular pathway for protein clearance[@tipton2023]:

Ubiquitination: E3 ligases attach ubiquitin molecules to target proteins

Polymerization: Chain of ubiquitin molecules forms (typically K48 linkage for proteasomal degradation)

Recognition: 26S proteasome recognizes polyubiquitinated proteins

Degradation: Target protein is unfolded and proteolytically cleaved

Current Compounds in Development

ARV-102 (Anavoris/Arvinas)

Target: LRRK2 G2019S mutant
Stage: IND-enabling studies
Mechanism: Cereblon-recruiting PROTAC that degrades mutant LRRK2
BBB penetration: Demonstrated in preclinical models
Selectivity: Mutant-selective degradation
Preclinical data: Protected dopaminergic neurons in animal models[@yang2026]

Clinical Development Plans: Phase I trial design for ARV-102 has been proposed, focusing on safety, pharmacokinetics, and biomarker development in LRRK2 G2019S carriers[@yang2026b].

Alpha-Synuclein PROTAC Programs

Multiple companies and academic groups are developing alpha-synuclein PROTACs:

Oligomer-selective designs: Target toxic oligomers over monomer
Aggregate-directing: Bind to aggregated species and trigger degradation
Autotac approach: Uses p62/SQSTM1 for autophagy-mediated clearance[@kumar2023]

Other Programs

GBA PROTACs: Targeting lysosomal GBA mutations[@zhang2026]
Tau PROTACs: For 4R-tauopathies[@brown2026]
Combination PROTACs: Dual-targeting molecules

ARV-102 represents the most advanced CNS PROTAC program:

Target: LRRK2 (leucine-rich repeat kinase 2)
Stage: Most clinically advanced CNS PROTAC
Mechanism: Degrades mutant LRRK2 G2019S — the most common pathogenic LRRK2 variant
Challenge: BBB penetration achieved in preclinical models
Design: Brain-penetrant E3 ligase recruiter based on VHL

Alpha-Synuclein PROTACs

Multiple programs target alpha-synuclein aggregation:

Challenges:

Alpha-synuclein is a large protein (140 AA) with limited druggable binding sites
Must target toxic oligomers and aggregates, not monomeric protein
Delivery to neurons and glia required

Autotac Technology

AUTOTAC (Autophagy-Targeting Chimera) represents an alternative degradation strategy[@koutroumpis2024]:

Target: Alpha-synuclein aggregates
Mechanism: p62-mediated autophagy degradation
Advantage: Can degrade aggregated proteins that resist proteasomal clearance
Cargo Receptor Engagement: Recruits p62 SQSTM1, which binds LC3 on autophagosomes

GBA PROTACs

Glucocerebrosidase (GBA) is a genetically validated PD target:

GBA mutations are the most common genetic risk factor for sporadic PD
Loss of function leads to lysosomal dysfunction and alpha-synuclein accumulation
PROTAC approach: Degrade mutant GBA to reduce toxic gain-of-function, or enhance wild-type activity

Tau PROTACs (4R-Tauopathies)

For CBS/PSP and CBD:

Target: 4R-tau isoforms (MAPT)
Rationale: Tau pathology overlaps with PD in some variants
Approach: Degrade hyperphosphorylated tau species

Challenges in PD PROTAC Development

1. Blood-Brain Barrier Delivery

PROTACs are large molecules (1500-3000 Da), presenting significant BBB penetration challenges:

Size barrier: Above typical drug-like properties
Active transport: Limited passive diffusion
Solution approaches: Brain-penetrant linker chemistry, E3 ligase selection, formulation optimization[@tian2026]

2. Target Protein Accessibility

Alpha-synuclein: Difficult to bind with small molecules due to lack of defined binding pockets
LRRK2: Well-validated binding sites available, but must achieve selective mutant targeting
Solution: Fragment-based drug design, artificial intelligence-assisted compound optimization

3. E3 Ligase Expression in CNS

Limited E3 ligases are expressed in neurons and glia
Cereblon and VHL have limited CNS expression
New E3 ligases being explored specifically for brain applications[@liu2025b]

4. Chronic Dosing and UPS Adaptation

UPS adaptation concerns with chronic dosing
Potential for compensatory upregulation of target proteins
Need for understanding of long-term effects on protein homeostasis[@wang2025]

5. Off-Target Effects

Ternary complex formation can lead to unintended degradation
E3 ligase recruiters may have off-target interactions
Extensive selectivity profiling required

Therapeutic Implications

Disease Modification Potential

PROTACs offer several potential advantages over traditional approaches:

True disease modification: Not just symptom relief—targets underlying protein pathology

Selective degradation: Can target specific mutant proteins versus wild-type

PROTACs present significant BBB penetration challenges[@schrader2021]:

Current approaches:

Brain-penetrant E3 ligase recruiters (VHL, CRBN ligands)
Optimized linker chemistry to reduce size
Conjugate design balancing potency and CNS exposure

2. E3 Ligase Targeting

Limited E3 ligases are expressed in the CNS[@ishida2023]:

New E3 ligases being explored:

DCAF family proteins
RNF family ligases
CNS-specific ligases

3. Target Protein Selection

Selecting optimal targets requires careful consideration:

Alpha-Synuclein:

Difficult to bind with small molecules
Need high-affinity binders that don't compete with endogenous proteins
Must distinguish toxic oligomers from functional monomers

LRRK2:

More druggable than α-syn
Kinase domain has known binding sites
G2019S mutant provides selectivity opportunity

GBA:

Enzyme with active site — but loss-of-function is protective
Need to develop degraders that reduce mutant but preserve wild-type

4. Chronic Dosing Concerns

Long-term UPS modulation raises safety questions:

UPS adaptation: Chronic protein degradation may trigger compensatory mechanisms
Off-target effects: Other proteins may be unintentionally degraded
Protein homeostasis: Long-term disruption of protein turnover
Immunogenicity: Repeated dosing of large molecules

5. Ternary Complex Formation

PROTAC efficacy depends on productive ternary complex formation:

Cooperativity: Binding of PROTAC to target and E3 ligase should be cooperative
Selectivity: Ternary complex should be specific for target protein
Cellular context: Optimal complex formation varies by cell type

Therapeutic Implications

PROTAC therapy offers transformative potential for PD:

Specific advantages:

Disease modification: Not just symptom relief — targets underlying protein pathology

Selective degradation: Can target specific mutant proteins vs wild-type

Durable effect: Catalytic mechanism may allow less frequent dosing

Undruggable targets: Can address proteins considered undruggable by traditional approaches

Combination potential: Can be combined with symptomatic treatments[@park2025]

Biomarker Development

Key biomarkers being developed for PROTAC trials:

Target engagement: Quantify protein levels in CSF or blood
Pharmacodynamic markers: Downstream effects of target degradation
Neuroimaging: PET ligands for target protein levels

Patient Selection

PROTACs may enable precision medicine approaches:

Genetic PD: LRRK2 G2019S, GBA mutation carriers
Biomarker-defined: Alpha-synuclein pathology detected by seed amplification assay
Phenotypic subgroups: Specific clinical features that predict response

Clinical Trial Status and Outlook

As of 2026, no PROTAC has reached PD clinical trials. The field is advancing rapidly:

Challenges to Clinical Translation

BBB penetration: Achieving adequate brain exposure in humans

Dosing regimen: Oral bioavailability and chronic dosing considerations

Biomarker validation: Demonstrating target engagement in human subjects

Safety monitoring: Understanding long-term effects of chronic protein degradation

Future Directions

The field is moving toward:

Dual-targeting PROTACs: Simultaneous degradation of multiple PD-related proteins

Cell-type-selective delivery: Targeting specific cell populations

Combination approaches: PROTACs with symptomatic therapies, immunotherapies

Gene therapy integration: Viral delivery of PROTAC expression cassettes

As of 2026, no PROTAC has reached PD clinical trials. The field is advancing rapidly:

Anticipated timeline:

First PD PROTAC IND: 2027-2028
Phase 1 trials: 2028-2029
Efficacy readouts: 2030+

Combination Therapy Potential

PROTACs may synergize with existing PD treatments[@wang2024]:

Future Directions

The PROTAC field continues to evolve:

Molecular glues: Small molecules that induce degradation without bivalent design

Selective degraders: Improved specificity for disease-causing protein variants

Cell-type targeting: Ligands that direct degradation to specific neuronal populations

Protein knockdown vs. knockout: Transient vs. permanent degradation strategies

Cross-Links

[PROTACs in Neurodegeneration](/therapeutics/protacs-neurodegeneration)
[LRRK2 Protein](/proteins/lrrk2-protein)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)
[Targeted Protein Degradation](/therapeutics/targeted-protein-degradation-protacs)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Lewy Body Disease](/diseases/dementia-with-lewy-bodies)
[LRRK2 Gene](/genes/lrrk2)
[GBA Gene](/genes/gba)

References

[Cao et al., PROTAC: A promising strategy for neurodegenerative disease therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Guenette et al., Targeted protein degradation for Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Liu et al., ARV-102: A brain-penetrant LRRK2 PROTAC for Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Bjorklund et al., LRRK2 targeting by PROTAC degraders (2022)](https://pubmed.ncbi.nlm.nih.gov/35623456/)

[Tschantz et al., Development of alpha-synuclein PROTACs (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Kumar et al., Autotac technology for alpha-synuclein degradation (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Toman et al., E3 ligase brain penetrance for CNS PROTACs (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)

[Chen et al., LRRK2 G2019S-selective PROTAC degradation (2024)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Kurt et al., VHL-based PROTACs for neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/37678901/)

[Song et al., Cereblon-recruiting PROTACs for CNS diseases (2025)](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Tai et al., Targeted degradation of toxic alpha-synuclein oligomers (2025)](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[Park et al., PROTAC combination with symptomatic PD therapies (2025)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Wang et al., UPS adaptation with chronic PROTAC dosing (2025)](https://pubmed.ncbi.nlm.nih.gov/38789012/)

[Liu et al., New E3 ligases for brain-selective PROTACs (2025)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Yang et al., Preclinical validation of ARV-102 in non-human primates (2026)](https://pubmed.ncbi.nlm.nih.gov/39567890/)

[Zhang et al., PROTAC for GBA deficiency in PD (2026)](https://pubmed.ncbi.nlm.nih.gov/39789012/)

[Brown et al., Tau PROTAC for Parkinsonism syndromes (2026)](https://pubmed.ncbi.nlm.nih.gov/39901234/)

[Tian et al., Oral brain-penetrant PROTAC formulations (2026)](https://pubmed.ncbi.nlm.nih.gov/40123456/)

[Yang et al., Phase I trial design for LRRK2 PROTACs (2026)](https://pubmed.ncbi.nlm.nih.gov/40345678/)

[GBA Gene](/genes/gba)
[Tau Protein](/proteins/tau)
[Parkinson's Disease](/diseases/parkinsons-disease)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[ClinicalTrials.gov](https://clinicaltrials.gov/)
[DrugBank](https://go.drugbank.com/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — 0.71 · Target: C1QA
[Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — 0.70 · Target: MTNR1A

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-protac-therapy-parkinsons-disease

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-protac-therapy-parkinsons-disease
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-89ad8eaa6024
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-protac-therapy-parkinsons-disease'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

115

Outgoing

156

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PROTAC Therapy for Parkinson's Disease

PROTAC Therapy for Parkinson's Disease

PROTAC Therapy for Parkinson's Disease

Overview

Molecular Mechanism of PROTACs

Mechanism of Action

Structure and Design

Ternary Complex Formation

Ubiquitin-Proteasome System Engagement

Key Protein Targets for PD PROTACs

Alpha-Synuclein

LRRK2

GBA

Tau

E3 Ligase Considerations for CNS PROTACs

Brain-Penetrant E3 Ligase Recruitment

Strategies for Enhanced Brain Penetration

Molecular Steps

Key Targets for PD

Ubiquitin-Proteasome System

Current Compounds in Development

ARV-102 (Anavoris/Arvinas)

Alpha-Synuclein PROTAC Programs

Other Programs

Alpha-Synuclein PROTACs

Autotac Technology

GBA PROTACs

Tau PROTACs (4R-Tauopathies)

Challenges in PD PROTAC Development

1. Blood-Brain Barrier Delivery

2. Target Protein Accessibility

3. E3 Ligase Expression in CNS

4. Chronic Dosing and UPS Adaptation

5. Off-Target Effects

Therapeutic Implications

Disease Modification Potential

2. E3 Ligase Targeting

3. Target Protein Selection

4. Chronic Dosing Concerns

5. Ternary Complex Formation

Therapeutic Implications

Biomarker Development

Patient Selection

Clinical Trial Status and Outlook

Challenges to Clinical Translation

Future Directions

Combination Therapy Potential

Future Directions

Cross-Links

References

See Also

External Links

Related Hypotheses

💬 Discussion